{"id":"biological-solrikitug-high-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Solrikitug works by binding to the IL-1β protein, thereby inhibiting its activity and reducing inflammation. This mechanism is thought to be beneficial in treating various inflammatory conditions.","oneSentence":"Solrikitug is a high-dose biologic that targets the IL-1β pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:24:20.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of Still's disease"}]},"trialDetails":[{"nctId":"NCT06496620","phase":"PHASE2","title":"A Study to Evaluate Solrikitug in Participants With COPD (ZION)","status":"RECRUITING","sponsor":"Uniquity One (UNI)","startDate":"2024-08-14","conditions":"COPD","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37999,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Biological: Solrikitug high dose","genericName":"Biological: Solrikitug high dose","companyName":"Uniquity One (UNI)","companyId":"uniquity-one-uni","modality":"Biologic","firstApprovalDate":"","aiSummary":"Solrikitug is a high-dose biologic that targets the IL-1β pathway. Used for Treatment of Still's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}